What BIOCODEX does

BIOCODEX is a privately held, family-founded French multinational pharmaceutical company established in 1953 and headquartered in Gentilly, France. The company operates across five therapeutic areas — microbiota, women's health, mental health, rare diseases, and established products/family health — with a diversified portfolio spanning prescription medications, medical devices, food supplements, dermo-cosmetics, and intimate care products. Its core technological foundation is the Saccharomyces boulardii CNCM I-745 strain, the world's first probiotic yeast commercialized globally since 1923 and deposited at the Institut Pasteur, supplemented by proprietary strains including Bifidobacterium longum 35624 (via PrecisionBiotics partnership), patent-protected Lactobacillus crispatus IP174178, and Bacillus coagulans/subtilis formulations. The company maintains vertically integrated manufacturing at its Beauvais facility and operates 16 wholly-owned subsidiaries and 100+ distribution partners across Africa, the Americas, Asia, and Europe, reaching 15+ countries for flagship brands.

BIOCODEX generates revenue through diversified product sales across consumer health, women's health, and pharmaceutical categories, distributed primarily through pharmacy and parapharmacy networks. The company reported EUR 677 million in revenue for fiscal year 2025 with a workforce of 1,900+ employees representing 40+ nationalities. Its go-to-market combines enterprise field sales targeting healthcare professionals (physicians, pharmacists, specialists) with consumer-facing brand marketing across dedicated product websites. Key sub-brands include SYMBIOSYS (probiotics including Alflorex+, Stomalex, Ultra-Protect ATB), THALAMAG (marine magnesium supplements with 30+ years of heritage), Saforelle (intimate care created 1989), Gestarelle (maternity, 30+ years), and Rap Phyto (circulation, 100 years of expertise). The company recently expanded into rare disease therapeutics through a strategic licensing agreement with THX Pharma (up to EUR 173 million in potential deal value for Batten-1 and TX01 treatments) and maintains a nine-year strategic partnership with PrecisionBiotics (Novonesis) for microbiome science collaboration. Additional revenue streams include licensing royalties from rare disease drug development. BIOCODEX holds family ownership with no disclosed external investors, subsidiaries including IPRAD PHARMA and Phardex, and holds certifications including AFNOR ISO 26000 and a Gender Equality Index score of 97/100.

Name

BIOCODEX

Legal name

BIOCODEX

Website

https://biocodex.fr

Company type

Private

Founded year

1953

Operating status

Operating

Headcount range

1,001–5,000 employees

Short description

BIOCODEX is a privately held French multinational pharmaceutical company founded in 1953 that develops and distributes probiotic, women's health, mental health, rare disease, and family health products across 15+ countries through 16 subsidiaries and 100+ distribution partners, reporting EUR 677M in 2025 revenue.

Ownership category

akta.pro rank

Product category

Microbiota Pharmaceuticals

NAICS

Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical Preparation Manufacturing (325412)

SIC

Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Microbiome Manufacturing, Formulation & Delivery Technologies (encapsulation, spores, oral delivery) (HLAAAFAJ)

akta.pro secondary industry

Bio-based Pharmaceuticals, Nutraceuticals & Specialty Bioactives (EUAAAIAK)

Keywords

• Pharmaceutical products
• Probiotic supplements
• Microbiota therapeutics
• Women's health products
• Rare disease treatments

Headquarters

HQ city

Gentilly

HQ country

France

HQ region

Europe

Offices4 records

Markets served

GTM type

B2C

Offering type

Hardware or Manufacturing

Cost components

Personnel, Operations, Marketing or Sales, Technology or R&D, Supply Chain

Revenue model

1. Pharmaceutical products: Prescription and over-the-counter medications including established products for gastroenterology, pain management, and ORL conditions. Revenue from drug formulations and medications.
2. Dietary supplements: Non-prescription supplements including probiotics (SYMBIOSYS, Alflorex+, ULTRA-PROTECT), magnesium-based products (THALAMAG), and specialized formulations for women's health (Gestarelle) and family health.
3. Medical devices: Medical devices including intimate care products (Saforelle Mucogyne ovules and gel) and dermo-cosmetics for women's intimate health.
4. Rare disease drug licensing: Licensing and commercialization rights for rare disease treatments (Batten-1, TX01) through partnership with THX Pharma, valued at up to EUR 173 million including upfront and milestone payments plus royalties.

Pricing tiers

Go-to-market motion2 records

Distribution channels5 records

Marketing channels5 records

Core offering

Biocodex develops, manufactures, and commercializes pharmaceutical products, dietary supplements, medical devices, and dermo-cosmetics built on microbiome science. Its portfolio spans five therapeutic areas — microbiota, women's health, mental health, rare diseases, and family health/established products — distributed through pharmacy and parapharmacy networks, 16 subsidiaries, and 100+ distribution partners across more than 15 countries.

Product overview

Biocodex is a multinational pharmaceutical company with a diversified portfolio organized around five therapeutic areas: Microbiota, Women's Health, Mental Health, Rare Diseases, and Established Products & Family Health. The core probiotic heritage stems from Saccharomyces boulardii CNCM I-745, the world's first probiotic yeast strain commercialized over 70 years ago. The product portfolio spans prescription medicines, medical devices (vaginal ovules and gels), food supplements (probiotics, magnesium, circulation, maternity), dermo-cosmetics, and intimate care products. Key sub-brands include SYMBIOSYS (probiotics including Alflorex+, Stomalex, Ultra-Protect ATB), THALAMAG (marine magnesium supplements), Saforelle (intimate care with Mucogyne and Physioflor sub-lines), Gestarelle (maternity), and Rap Phyto (leg circulation). The company operates 16 subsidiaries and 100 distribution partners globally with 2025 revenue of €677 million.

Differentiator

Problem solved

Functional benefit

Brands

• Saforelle: Intimate hygiene and care product line for women
• Gestarelle
• Rap Phyto
• Thalamag
• Myleuca
• DE(RAMP)
• SYMBIOSYS
• SYMBIOSYS ALFLOREX+
• ULTRA-PROTECT ATB
• SYMBIOSYS STOMALEX
• DIFRAVISION
• Saforelle Mucogyne
• Physioflor
• Biocodex Microbiota Foundation

Products and services

• SYMBIOSYS Alflorex+ Probiotic supplement containing the proprietary Bifidobacterium longum 35624 strain, isolated from healthy human intestines, designed to restore intestinal flora balance and digestive comfort. Developed in partnership with PrecisionBiotics and APC Microbiome Ireland.
• SYMBIOSYS Stomalex Probiotic supplement combining Bacillus coagulans MY-01 and Bacillus subtilis MY-02 strains with ginger extract to support intestinal flora balance and normal stomach function.
• ULTRA-PROTECT ATB Food supplement for special medical purposes containing the Saccharomyces boulardii CNCM I-745 probiotic strain, zinc, vitamin C, and vitamin D3 to support immune function and intestinal flora balance during antibiotic treatment.
• Saforelle Mucogyne Ovules Non-hormonal vaginal ovules based on hyaluronic acid for restoring vaginal mucosa, promoting cellular repair, maintaining hydration, and supporting natural pH balance. CE marked medical device.
• Saforelle Mucogyne Gel Non-hormonal intimate gel with liposomal hyaluronic acid for restoring vulvovaginal mucosa, providing lubrication, hydration, and flexibility for intimate comfort.
• Saforelle Mucogyne Voie Orale Food supplement with ExceptionHYAL hyaluronic acid complex, vitamin B8 for mucosal maintenance, and wheat ceramides for skin elasticity support in intimate care.
• Saforelle Physioflor Oral First food supplement for intimate flora composed of 100% Lactobacillus crispatus, a patented probiotic strain supporting vaginal health.
• Physioflor AC Medical device - acidifying vaginal gel containing lactic acid, glycerol, and alpha-glucan oligosaccharides for treating bacterial vaginosis symptoms and preventing recurrence.
• Gestarelle G+ Prenatal supplement recommended from pre-conception through pregnancy and breastfeeding, providing essential vitamins, folic acid (Quatrefolic), iron, iodine, vitamin D, and Omega-3 for fetal development.
• Gestarelle Fertilité Preconception supplement combining zinc for normal fertility, selenium for immune protection, iodine for thyroid function, and vitamin B9 (Quatrefolic) for neural tube defect prevention.
• Gestarelle Huile Vergetures Maternité Bio stretch mark oil with sweet almond oil, Centella asiatica extract, and vitamin E for preventing stretch marks and improving skin elasticity during pregnancy.
• THALAMAG Equilibre Intérieur LP Marine magnesium supplement from the Irish Sea using Sepismart SR technology for extended release, providing 300mg of magnesium per day to reduce fatigue and support nervous system function.
• THALAMAG Boost Energy and tonicity supplement combining marine magnesium with cola nut and spirulina for sustained energy support.
• THALAMAG Immunité Immune support supplement with marine magnesium from the Irish Sea, iron, and folate (vitamin B9) contributing to normal immune system function.
• THALAMAG Plasma Marin Marine plasma supplement based on René Quinton's discovery, combining seawater with magnesium and selenium for fatigue reduction and immune function support.
• MYLEUCA Cleansing body wash solution with Tea Tree (Melaleuca alternifolia) oil for sensitive skin prone to cutaneous mycosis, with a gentle alkaline pH of 8.5.
• DE(RAMP) Comprimés Food supplement for normal muscle function containing magnesium, potassium, and copper to support muscle recovery and energy metabolism.
• DE(RAMP) Gel Muscle comfort gel with Wintergreen essential oil, Arnica montana extract, and menthol for a cooling and relaxing effect on tired muscles.
• Rap Phyto Crème Apaisante N°1 leg lighter cream formulated with natural ingredients including horse chestnut, broom flower, and Arnica montana for relieving and toning tired legs.
• Rap Phyto Gel Fraîcheur Menthol Certified bio cooling gel with menthol and natural active ingredients for instant and prolonged cooling sensation to relieve tired legs.
• Rap Phyto Gel Fraîcheur Agrumes Certified bio citrus-scented cooling gel providing instant freshness and toning effect for fatigued legs.
• Rap Phyto Jambes Légères Food supplement with horse chestnut extract and blackcurrant for normal venous circulation, combined with vitamin C for normal blood vessel function.
• DIFRAVISION Food supplement with blueberry extract, vitamins C and E, zinc, selenium, DHA, lutein, and zeaxanthine for vision health and cellular protection against oxidative stress.
• Batten-1 (licensed rare disease treatment)

Quantifiable outcome

• Alflorex available in 15+ countries through PrecisionBiotics partnership
• +3 more outcomes

Named customers1 record

Segments5 records

Ideal customer profiles5 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Three partnerships are on record, tiered core and minor.

• PrecisionBiotics (Novonesis)coreStrategic or Co-development Partner · 23 April 2026Nine-year strategic partnership formalized at leadership meeting in Copenhagen for microbiome science and consumer health. Expansion of scientific collaboration and market reach for flagship product Alflorex, now available in over 15 countries. New agreement expected to accelerate growth by deepening scientific collaboration and unlocking new market opportunities. Novonesis formed from Chr. Hansen-Novozymes merger.
• THX Pharma (Theranexus)coreStrategic or Co-development Partner · 11 February 2026Strategic licensing agreement for development and commercialization of treatments for three rare diseases. Biocodex acquired exclusive worldwide rights for Batten-1 (juvenile Batten disease) and exclusive US/Canada rights for TX01 (Gaucher and Niemann-Pick type C diseases). Deal valued at up to EUR 173 million including EUR 12 million upfront, milestone payments, and tiered double-digit royalties. THX Pharma leads clinical development while Biocodex handles compassionate use, market access, and commercialization. Phase 3 trial for Batten-1 planned for 2026 with international launch targeted around 2030.
• Biocodex Microbiota FoundationminorOthersCorporate foundation funded by Biocodex supporting microbiota research. Opens annual applications for EUR 35,000 research grant to Canadian academics and scientists for microbiota-related research projects lasting 1-2 years. 2026 applications due October 30, with selection announced November 30. 2025 recipient was Dr. Xiaopeng Bai from McMaster University for stress-microbiota-intestinal barrier axis research.

Scale indicators11 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• Novonesis (Chr. Hansen): Global leader in microbial and fermentation solutions with a dedicated Health & Nutrition probiotics business (formerly Chr. Hansen). Directly comparable as a microbiome/probiotic platform serving consumer health and pharma customers, and Biocodex's stated strategic partner through PrecisionBiotics.
• BioGaia: Swedish probiotics specialist selling clinically documented Lactobacillus and Bifidobacterium strains via OTC, pharmacy, and prescription channels. Highly comparable to Biocodex in business model (proprietary probiotic strains, pharma distribution, women's and gut health focus) though smaller in scale.
• Lallemand Health Solutions: Canadian probiotic manufacturer producing proprietary yeast (Saccharomyces boulardii) and bacterial strains for pharma and supplement brands globally. Directly competes with Biocodex in the probiotic strain and formulation space and serves overlapping B2B and branded customers.
• Probi: Swedish probiotic R&D and B2B supplier with clinically validated Lactobacillus plantarum strains licensed to consumer health and pharma brands. Comparable as a science-led probiotic platform serving similar end-markets (gut health, women's health, immune support).

Broad incumbents

• Yakult Honsha: Japanese multinational built around a proprietary Lactobacillus casei Shirota strain with global distribution in probiotic dairy and supplements. Comparable as a globally scaled, single-strain probiotic franchise, though delivery vehicle is primarily fermented dairy rather than supplements.
• Danone (Essential Dairy & Plant-Based / Medical Nutrition): Global food and nutrition major with large probiotic and microbiome exposure (Activia, Actimel, medical nutrition brands). Comparable in end-market overlap (digestive health, women's health, infant nutrition) but operates at vastly larger scale and broader portfolio than Biocodex.
• Bayer Consumer Health: Division of Bayer selling OTC pharma, probiotics, and women's health brands globally through pharmacy and mass retail. Comparable in target categories (women's health, gut health, OTC pharma) though it operates across a much broader portfolio and larger geographic footprint.
• Sanofi Consumer Healthcare: French-headquartered global pharmaceutical major with a dedicated Consumer Healthcare business spanning women's health, digestive health, and probiotics. Comparable in target therapeutic areas and pharmacy-channel GTM, though at much larger scale and with broader R&D capabilities.

Regional players

• Pierre Fabre: French privately held pharmaceutical and dermo-cosmetic group with strong pharmacy-channel presence in women's health, dermatology, and consumer health. Highly comparable as a French independent pharma peer with similar pharmacy distribution model, family-ownership heritage, and women's health focus.

Emerging players

• Theranexus: French clinical-stage biotech developing treatments for rare neurological diseases including Batten-1 and TX01. Biocodex is its licensing partner and exclusive worldwide commercialization partner for these assets, making it a directly relevant biotech counterpart in the rare disease pipeline.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat5 records

Key risks5 records

Key highlights6 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Subsidiaries2 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Investments1 record

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about BIOCODEX